🇺🇸 elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil in United States
6 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 6
Most-reported reactions
- Drug Interaction — 1 report (16.67%)
- Dysphagia — 1 report (16.67%)
- Nasal Congestion — 1 report (16.67%)
- Rash Erythematous — 1 report (16.67%)
- Rash Pruritic — 1 report (16.67%)
- Rhabdomyolysis — 1 report (16.67%)
Other Infectious Disease / Virology approved in United States
Frequently asked questions
Is elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil approved in United States?
elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil in United States?
Fundacion Clinic per a la Recerca Biomédica is the originator. The local marketing authorisation holder may differ — check the official source linked above.